Literature DB >> 29584585

Journey of siRNA: Clinical Developments and Targeted Delivery.

Rahul R Nikam, Kiran R Gore1.   

Abstract

Since the evolutionary discovery of RNA interference and its utilization for gene knockdown in mammalian cell, a remarkable progress has been achieved in small interfering RNA (siRNA) therapeutics. siRNA is a promising tool, utilized as therapeutic agent against various diseases. Despite its significant potential benefits, safe, efficient, and target oriented delivery of siRNA is one of the major challenges in siRNA therapeutics. This review covers major achievements in clinical trials and targeted delivery of siRNAs using various targeting ligand-receptor pair. Local and systemically administered siRNA drug candidates at various phases in clinical trials are described in this review. This review also provides a deep insight in development of targeted delivery of siRNA. Various targeting ligand-siRNA pair with complexation and conjugation approaches are discussed in this review. This will help to achieve further optimization and development in targeted delivery of siRNAs to achieve higher gene silencing efficiency with lowest siRNA dose availability.

Entities:  

Keywords:  GalNAc; RNA interference; clinical trial; gene silencing; siRNA; targeted delivery

Mesh:

Substances:

Year:  2018        PMID: 29584585     DOI: 10.1089/nat.2017.0715

Source DB:  PubMed          Journal:  Nucleic Acid Ther        ISSN: 2159-3337            Impact factor:   5.486


  33 in total

1.  Cyclodextrins in drug delivery: applications in gene and combination therapy.

Authors:  Rebecca M Haley; Riccardo Gottardi; Robert Langer; Michael J Mitchell
Journal:  Drug Deliv Transl Res       Date:  2020-06       Impact factor: 4.617

2.  Supportive Oligonucleotide Therapy (SOT) as an Alternative Treatment Option in Cancer: A Preliminary Study.

Authors:  Ioannis Papasotiriou; Georgios Beis; Aggelos C Iliopoulos; Panagiotis Apostolou
Journal:  In Vivo       Date:  2022 Mar-Apr       Impact factor: 2.155

3.  Non-coding RNAs in Neonatal Necrotizing Enterocolitis.

Authors:  Keyur Donda; Benjamin A Torres; Akhil Maheshwari
Journal:  Newborn (Clarksville)       Date:  2022-03-31

4.  Preparation and Characterization of Ginger Lipid-derived Nanoparticles for Colon-targeted siRNA Delivery.

Authors:  Junsik Sung; Chunhua Yang; James F Collins; Didier Merlin
Journal:  Bio Protoc       Date:  2020-07-20

Review 5.  Leading RNA Interference Therapeutics Part 2: Silencing Delta-Aminolevulinic Acid Synthase 1, with a Focus on Givosiran.

Authors:  Pedro Renato de Paula Brandão; Simoneide S Titze-de-Almeida; Ricardo Titze-de-Almeida
Journal:  Mol Diagn Ther       Date:  2020-02       Impact factor: 4.074

6.  PD-L1 siRNA-mediated silencing in acute myeloid leukemia enhances anti-leukemic T cell reactivity.

Authors:  Diede van Ens; Charlotte M Mousset; Tim J A Hutten; Anniek B van der Waart; Diana Campillo-Davo; Sanne van der Heijden; Denise Vodegel; Hanny Fredrix; Rob Woestenenk; Loreto Parga-Vidal; Joop H Jansen; Nicolaas P M Schaap; Eva Lion; Harry Dolstra; Willemijn Hobo
Journal:  Bone Marrow Transplant       Date:  2020-06-11       Impact factor: 5.483

Review 7.  Reprogramming of mitochondrial proline metabolism promotes liver tumorigenesis.

Authors:  Zhaobing Ding; Russell E Ericksen; Qian Yi Lee; Weiping Han
Journal:  Amino Acids       Date:  2021-02-28       Impact factor: 3.520

Review 8.  Small interfering RNAs (siRNAs) in cancer therapy: a nano-based approach.

Authors:  Ghanbar Mahmoodi Chalbatani; Hassan Dana; Elahe Gharagouzloo; Santiago Grijalvo; Ramon Eritja; Craig D Logsdon; Fereidoon Memari; Seyed Rouhollah Miri; Mahdi Rezvani Rad; Vahid Marmari
Journal:  Int J Nanomedicine       Date:  2019-05-02

Review 9.  Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD.

Authors:  Marja-Riitta Taskinen; Chris J Packard; Jan Borén
Journal:  Curr Atheroscler Rep       Date:  2019-05-20       Impact factor: 5.113

Review 10.  RNA-based scaffolds for bone regeneration: application and mechanisms of mRNA, miRNA and siRNA.

Authors:  Qiuping Leng; Lini Chen; Yonggang Lv
Journal:  Theranostics       Date:  2020-02-10       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.